PainChek lifts ARR 24.6% as loss reaches $8.94 million

Auditor flags funding uncertainty

PainChek Limited (ASX:PCK) ended FY2026 with a stronger commercial footprint but a balance sheet still dependent on future execution and funding. BDO issued an unmodified audit opinion, while drawing attention to a material uncertainty that may cast significant doubt over the group’s ability to continue as a going concern.

The warning sits alongside a $8.94 million net loss, up from $7.67 million a year earlier, and net operating cash outflows of $9.24 million, compared with $6.75 million in FY2025. PainChek had $5.99 million in cash at 30 June 2026, while current liabilities included $4.25 million related to its convertible notes. The directors said continued commercialisation and the ability to raise capital when necessary supported preparation of the accounts on a going-concern basis.

Recurring revenue grew ahead of customer revenue

The operating metrics were more encouraging than the statutory result. Customer revenue increased 11.4% to $3.74 million, customer receipts rose 13.6% to $4.00 million and implemented annualised recurring revenue climbed 24.6% to $4.46 million. Implemented licences increased 27.9% to 90,198, while active customer sites rose 19.5% to 1,990 and cumulative digital pain assessments reached 21.38 million.

Customer retention remained approximately 85% globally, with Australia reported at 93%. Yet the company acknowledged that commercial conversion did not meet expectations in every area. That admission is important: the report’s central distinction is between agreements and pipeline, which create opportunity, and implemented licences, revenue and receipts, which demonstrate execution.

US expansion moves from clearance to deployment

US commercialisation is the main test of that execution agenda. PainChek said its October 2025 FDA De Novo clearance established a regulatory pathway for PainChek Adult in long-term care, skilled nursing and memory care. During FY2026, it commenced its first two deployments under an agreement with Sabra Health Care REIT, which provides a framework to pursue facilities representing up to 20,000 beds. The figure describes potential network access, not committed deployments or guaranteed revenue.

The company has also established relationships involving PointClickCare and Eldermark integrations, and participates in the Mayo Clinic Platform Accelerate programme. Management’s FY2027 priorities are to convert qualified US opportunities into deployments, increase implementation within existing UK customer groups and expand utilisation across its established Australian and New Zealand base.

Capital raised, but convertible debt adds pressure

PainChek raised $7.5 million through a share placement and $1.09 million from option exercises during the year. It also issued $5.5 million of convertible notes on 21 May 2026. The notes carry a 12% annual cash interest rate over a 12-month term and may convert at $0.195 a share, with the accounting recognising $4.25 million as current debt and $1.39 million as an equity component.

Costs increased as the company built its North American operation. Marketing and business development expense rose to $5.06 million from $4.04 million, while corporate and administration costs increased to $3.70 million. Research and development expense fell to $3.32 million from $3.78 million after FDA clearance, as resources shifted towards the core product and priority commercial markets. The company subsequently received a $1.12 million R&D tax incentive refund in July 2026, but the annual report does not present that payment as a solution to the broader funding uncertainty.

New leadership inherits a conversion problem

The leadership reset is designed around that gap between access and revenue. Lil Bianchi became chair in May 2026, former managing director Philip Daffas resigned as a director in July, and US-based healthcare executive Karen Holzberger commenced as chief executive officer in August. PainChek says the new operating focus is to qualify the pipeline more tightly, shorten implementation timeframes, increase customer utilisation and direct resources towards opportunities capable of producing recurring revenue.

That creates a clear but demanding FY2027 scorecard: deployments under the Sabra framework, conversion of the US pipeline, faster activation of contracted licences and sustained receipts from the existing customer base. The next set of results will need to show not only that the opportunity exists, but that it is arriving quickly enough to narrow the cash gap identified by the auditor.